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ABSTRACT
Breast cancer is a disease that continues to take the life of approximately 40,000 men and
women in the United States each year [1]. Tumor drug resistance represents a major problem
for the treatment of many breast cancer patients. The mechanisms underlying such resistance
remain to be elucidated, and one approach to study this issue involves the development of
tumor drug-resistant breast cancer models in mice. HER-2 positive breast cancer is
considered to be one of the most aggressive subtypes of breast cancer and has become a
major target for treatment. HER-2 status is a routinely checked marker for breast cancer due
to as many as 1/5 of patients overexpressing this gene, thus making it an ideal model to
approach drug resistance in tumors. In this project, two human breast cancer models, derived
from the HER-2 positive BT747 and MDA-MB-361 cell lines, will be characterized.
Parental and drug sensitive populations were studied, which included the evaluation of the
levels of protein expression of components of the HER-2 signaling pathway. A second
approach involved intracardiac injection of tumor cells in mice to generate widespread
metastases, and the subsequent evaluation of relative drug resistance to chemotherapy in
metastases to different organs. Lastly, intracranial injection of cancer cells employed to
address the increasing incidence of brain metastasis in breast cancer patients.
My dissertation aims to uncover mechanisms by which cancer cells develop drug resistance,
developing models of late-stage breast cancer and the combination of these models with
metronomic chemotherapies.
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1: INTRODUCTION
Cancer will claim the life of approximately 12 million lives worldwide in the year 2020[1]. Cancer
is uncontrolled and malignant growth of cells, which results from a collection in mutations in
specific genes. These changes include the upregulation of oncogenes and downregulation (or
inactivation) of tumor suppressor genes [2]. There are a number of characteristics that can
differentiate a benign tumor from a malignant one, and chief among these is the ability of the latter
to metastasize (i.e., spread to other parts of the body). As cancers grow, they can accumulate
additional mutations that can help them grow even in hypoxic environments, in those lacking
specific nutrients [3], or even in the presence of administered anti-cancer drugs. Some cancers,
when diagnosed, appear to contain subpopulations of cells intrinsically resistant to anti-cancer
drugs, while in other cases tumors can develop such resistance de novo during treatments (socalled acquired resistance). In addition, cancer cells can gain the ability to bypass many apoptotic
signals through a diverse repertoire of pathways, so they continue to grow and proliferate. Current
therapies for cancer include surgery, radiation, chemotherapy, with the most problematic cancers
being those resistant to chemotherapy and radiation after surgery is no longer feasible. Additional
therapies include targeted therapies that stop cancer cell progression through targeting receptors
responsible for growth and survival, or by activating the immune system (via targeting molecules
such as CTLA-4 or PD-1). Although these approaches have been useful in increasing the survival
of breast cancer patients (e.g., metastatic HER-2 positive breast cancers show significant
responses to anti-HER-2 drugs in combination with chemotherapy), the death rate for this disease
remains high.
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To improve our understanding of these issues, I have studied models that reflect different aspects
of tumor progression and drug resistance and I have coupled this analysis with the administration
of metronomic chemotherapy.

1.1 Drug Resistance in Cancer
Treating disseminated cancers has met with limited success, in part because tumors can develop
resistance to conventional chemotherapy. For example, ovarian cancers and small cell lung
carcinomas respond well to chemotherapy and regress, but may subsequently develop acquired
drug resistance [4]. Other types of cancers such as melanomas and prostate cancers are difficult
to treat as they are reportedly intrinsically resistant to chemotherapy [4]. Current hypothesis
suggest that cancers can evade therapy through different mechanisms, some of which are tumor cells
specific and other cause changes in the microenvironment [5], such as the via the overexpression
of Vascular Endothelial Growth Factor (VEGF).
Drug resistance can also arise through dysregulated apoptosis providing an imbalanced
environment leading to irreversible changes in a cell that can render chemotherapeutics less
effective [4]. The expression of some cytokines has also been implicated in aiding tumor cells to
evade chemotherapy [6]. However, there is uncertainty over the different mechanisms by which
cancer become drug resistant to current therapies, and that is in part what this dissertation seeks
to address.

1.2 Metastasis
Metastasis occurs when a tumor seeds and begins to grow at a distant site. Most cancer fatalities are
a consequence of metastasis and lack of response to chemotherapy. Patients are not infrequently
diagnosed with cancer at an advanced stage, with tumors that have already metastasized, making
it extremely difficult to eradicate the disease. One complicating factor can be the heterogeneity
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of tumors, which means they may contain subpopulations intrinsically resistant to currently
available therapies (even before any treatment is administered). During progression to late stage
cancer, tumor cells can begin to develop characteristics that allow them to lose cell polarity, cell
to cell adhesion, which can result in the tumor becoming invasive, thus increasing the likelihood
for metastasis to occur [7]. Tumor progression can also be promoted by (non-malignant) cell
populations residing in the tumor microenvironment, one example of this is the tumor associated
macrophages (TAMs) that can secrete proteins that facilitate the local invasion of malignant cells
[8]. This includes TAMS destruction of the basement membrane and invading the stroma and that
can help through the secretion of proteases [9]. Next, tumor cells must infiltrate the blood
circulation, intravasate, and survive long enough to exit the blood stream as to invade secondary
sites. Assuming these circulating tumor cells survive (presently, available data suggest most cells
do not survive in the circulation), they can invade a distant organ, arrest, and give rise to a
secondary tumor (i.e., a metastasis).
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1.3 Specific Aims
Specific Aim 1: Characterization of cell line models of HER-2 positive breast cancer.
Two HER-2 positive breast cancer cell lines were used to develop new in vivo tumor models to
study the disease. BT474 and MDA-MD-361 cell lines have been selected for tumorigenicity,
and/or acquired drug resistance, after implantation in mice. The ‘parental’ cell lines were
compared against the selected ‘variant’ subpopulations to determine if there are significant
differences in protein and gene expression levels. These models will be used to further evaluate
responses to anti-HER-2 therapies (which are routinely used clinically for the treatment of these
types of cancer), and the development of resistance to such therapies.
Specific Aim 2: Widespread Metastasis
Intracardiac injection of breast cancer cells was used to create a widespread metastasis model in
vivo. Once models were established, these were studied to determine if the spread of cancer to
different organs produces tumor deposits with different levels of drug resistance to given
treatments. A second approach to study metastasis in late-stage cancers was to analyze the effect
of metronomic chemotherapy in clinical patients. Together, these aim to test the hypothesis that
drug resistance is organ dependent.
Specific Aim 3: Modeling Brain Metastasis
In order to create a breast metastasis models in the brain, intracranial injections were used to
directly implant breast cancer cells in vivo. Tumor progression was monitored using the In Vivo
Imaging System (IVIS). As tumors increased in size, they were randomized into experimental and
control groups, which were then be used to test currently available chemotherapies using a
metronomic approach.
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2: BREAST CANCER
Breast cancer is a disease that affects over 3 million women worldwide and it is expected to
take the life of over 40,000 women and men in the United States [1]. There are different
subtypes of breast cancer and identification of specific subtypes for a given patient can help
oncologists chose the most effective chemotherapy-based regimen to treat metastatic disease.
For example, one routinely checked marker in breast cancers is HER-2. If a patient is
diagnosed with HER-2 positive breast cancer (i.e., because of abnormally high expression of
HER-2 in the tumor, the presence of HER-2) that defines the patient has having one of the
most aggressive subtypes of breast cancer (i.e., HER-2 positive)– that is associated with a
poor prognosis [9].

2.1 HER-2 positive Breast Cancer
HER-2 positive breast cancer is characterized by the overexpression of the Human
Epidermal Growth Factor Receptor-2 (HER-2). Figure 1 shows cancer cells taken from a
FVB/N-T (MMTVneu) 202Mul mouse (HER-2 positive) and 4T1 cells (HER-2 negative
murine breast cancer cell line). HER-2 is endogenously expressed in different tissues such
as the breast and ovaries. Is overexpressed in about 25% of breast cancer patients [10]. HER2 as a surface tyrosine kinase receptor, which plays an important role in signaling for growth,
proliferation, and survival in normal cells (Figure 2). Overexpression of HER-2 (or ErBb2),
leads to enhanced cell proliferation and survival. Overexpression of HER-2 has been shown
to promote tumor progression in mice, and in humans HER-2 overexpression in breast tumors
is associated (as noted above) with a poor prognosis [10]. If a patient is diagnosed with HER2 positive breast cancer, they are eligible for treatment with anti-HER-2 drugs
5

such as trastuzumab, trastuzumab emtansine, or lapatinib, which typically are given in
combination with chemotherapy for those patients with metastatic disease. For example,
Herceptin is used in combination with paclitaxel for the first line treatment of metastatic
HER-2 positive breast cancer [11]. Although a number of patients respond to such treatment,
drug resistance eventually develops in most cases.
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Figure 1. HER-2 receptor comparison in murine cell lines. Protein analysis of FVB/N-T
(MMTVneu) 202Mul/ and 4T1 murine cell lysates. FVB/N-T (MMTVneu) 202Mul/ shows
expression of HER-2 protein and 4T1 is used as a negative control. Both lanes show tubulin
as a loading control.

Figure 2. HER-2 transmembrane receptor visualized using florescence. Tumor tissue taken
from FVB/N-T (MMTVneu) 202Mul/mice. These mice express HER-2 throughout the cells in
their body.
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2.2 HER-2 Receptor
The HER-2 protein is encoded by the ErBb2 gene. It is a tyrosine kinase receptor composed of
an extracellular domain that can form dimers in the presence of any of its family of receptors. The
intracellular domain of the protein can become phosphorylated following dimerization, and this
initiates a signal transduction pathway (that stimulates cell division). The extracellular domain is
made up of four different subdomains (Figure 3). Subdomain I and III can form binding sites for
potential ligands and subdomains II and IV are cysteine-rich domains involved in dimerization
[12]. The protein also has a dimerization arm, which is a short hairpin loop in subdomain II that
contacts the partnering receptor.

2.3 HER-2 Targeted Therapy
Patients with HER-2 positive breast cancer are eligible for HER-2 targeted therapies, such as the
anti-HER-2 antibody, trastuzumab, or the small molecule tyrosine kinase inhibitor lapatinib,
among others. For example, trastuzumab is a monoclonal antibody that binds to the extracellular
subdomain IV of HER-2 and keeps the receptor from dimerizing. This leads to the inhibition of the
signaling cascade of both the Mitogen-Activated Protein Kinase (MAPK) and Phosphoinositide
3-kinase (PI3K/Akt) pathways which drive cell growth, proliferation, and cell cycle arrest [12].
Pertuzumab is another HER-2 targeted antibody that binds to its specific domain II, which prevents
ligand-activated heterodimerization, inhibiting HER-2 driven proliferation (Capelan, 2012).
Dimerization of HER-2 and HER-3 is the most mitogenic, potent, and most commonly found in
cancer cells [10]. When combined with chemotherapy (e.g. paclitaxel), trastuzumab can improve the
overall survival of patients with metastatic HER-2 positive breast cancer.
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2.4 Resistance to HER-2 Targeted Therapy
Resistance to HER-2 targeted therapy is common among women with overexpression of this
receptor and as many as 40-60% of HER-2 positive breast cancer patients do not respond [13].Some
of the most commonly used HER-2 targeted therapies available are Trastuzumab (Trade name
Herceptin), Lapatinib (Trade name Tykerb), Pertuzumab (Trade name Perjeta), and Trastuzumab
emtansine dm-1 (Trade name Kadcyla). Herceptin is a monoclonal antibody that binds to domain
IV of the HER-2 receptor, thus inhibiting dimerization and signaling cascade. Herceptin has been
approved since 2008, for the treatment of HER-2 positive breast cancer. However, drug resistance
remains a problem for many patients treated with Herceptin. Lapatinib is a small molecule tyrosine
kinase inhibitor that targets the ATP-binding pocket in both EGFR and HER-2 and has been
approved in the clinic for advanced breast cancer in combination with capecitabine after
trastuzumab and chemotherapy regimens have failed [14]. p95HER-2 is a truncated form of HER2 and the resistance to Herceptin is often linked to the loss of function of phosphatase and tensin
homolog (PTEN), responsible for regulating the PI3K pathway. Mutations in PTEN or inactivation
of PI3K pathway result in active HER-2 signaling, thus preventing inhibition of cell growth by
trastuzumab [15]. The Nagata group suggested that tumors with loss of PTEN, have a lower
response to trastuzumab than patients with PTEN-expressing tumors [16].Another group treated
HER-2 positive breast cancer patients with trastuzumab and came to the conclusion that PTEN,
PI3K, and HER3 play critical roles in its resistance mechanism [15]. Changes to HER-2 have also
been implicated in drug resistance to HER-2 targeted therapy. While some cancers lose HER-2
amplification, others begin to accumulate the truncated version of HER- 2, p95HER2. p95HER2 is
constitutively active, will respond to lapatinib, but not trastuzumab [16]. Trastuzumab is not
effective in the interruption of the potent HER-2 and HER-3 heterodimers,
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which contribute to the production of its ligands and together with the upregulation of HER-3,
making trastuzumab futile [17], [18]. Resistance to lapatinib involves the mutation of the HER-2
tyrosine kinase domain [14].Trowe and his team found 17 mutations in the HER-2 tyrosine kinase
domain that contribute to drug resistance to Lapatinib. The two mutations found typically
associated with lapatinib resistance in HER-2 were L755S and T798I and T790M in EGFR [14].

2.5 Characterization of new HER-2 positive breast cancer cell lines
BT474 is a human breast cancer cell line, which was derived from a breast cancer brain metastasis
that occurred in Caucasian female with a ductal carcinoma of the breast. The MDA-MD-361 cell
line was derived from metastatic adenocarcinoma in a 40-year-old female. These breast cancer cell
lines have been used for many years to study the aspects of HER-2 positive breast cancer [17]–
[20]. Expression of various proteins, either members of the HER family of proteins or of
downstream signal transduction mediator proteins, is being carried out as part of a characterization
study of BT474 and MDA-MB-361, and of variants of these lines that were derived by the PI
(Francia) – as detailed below. Such studies may provide additional data on potential biomarkers
for drug resistance. For example, literature suggests that when HER-2 targeted therapy is
administered, there is an increased expression of HER-3, another receptor belonging to HER family
[21]. We have tested to determine if such an observations can be confirmed in our breast cancer
models (Fig. 3).
MDA-MD-361 and BT474 cell lines were grown in RPMI at 37°C supplemented with 10%FBS
and 2mM L-glutamine and in a humidified atmosphere with 5% CO2.
For in vivo growth, cells were collected using 1% trypsin-EDTA, washed in PBS (Phosphate
Buffered Saline), and 2x106 cells were implanted orthotopically into the mammary fat pad of
SCID mice. Tumors grew very slowly, and variants were eventually isolated and
12

passaged several times in vivo to generate variants with enhanced tumorigenicity
up to three years (Fig. 3). In parallel, some tumors were allowed to grow to around
250mm3, at which point the mice were treated with the antiHER-2 antibody trastuzumab
(20mg/kg twice weekly) [20]. When primary tumors became resistant to the monoclonal
antibody therapy and reached 500mm3 in size, these were resected surgically (Figure 3), and
drug resistant variants were grown in tissue culture.

SCID mice

Primary tumor

metastasis

selection

Surgical resection

Metastasis
selection

Therapy

Therapy

Figure 3. Tumor Selection in vivo. SCID mice implanted serially with HER-2 positive human
tumors over a period of 3 years to select for drug resistant variants.
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2.6 RNA Sequencing
RNA sequencing permits whole transcriptome analysis and can reveal differences in variant cell
populations versus their parental counterparts. Through this process, we were able to begin to draw
a map (in transcription) that reflect in part the process of adaptation through passaging of these cell
lines. This analysis does not incorporate modifications, mutations in single-nucleotide
polymorphism, and does not always reflect overall changes in gene expression at the protein level.

2.7 Preparation of RNA
RNA extraction was carried out using Trizol on fresh cell pellets grown in tissue culture. Once
cells were homogenized with Trizol, equal amounts of chloroform and phenol were added,
homogenized again until clumps were no longer visible. Mixture was then vortexed and left
incubating on ice for 5 minutes. The mixture was then centrifuged for 15 min at 4 degrees to
retrieve the supernatant (RNA). RNA was transferred to a new microtube with 500ml of
isopropanol and stored at -20 degree. In order to assess RNA integrity, samples were run on a 1%
agarose gel. The RNA-seq analysis was carried out by Otogenetics in Atlanta, GA.

2.8 Results
Examples of protein expression levels of MDA-MB-361 and BT474 (parental) cell lines, and
variants are shown in Figure 4. To determine the the frequency of these changes in protein with the
development of drug resistance. Extensive western blot analyses were also performed in proteins
important in MAPK and PI3K/AKT pathways, such as AKT, using these cell lines. Figure 4B shows
a decrease in protein expression in the variant cell line 361p3 in both Rag C and E- cadherin. Ecadherin is an important protein involved in cell to cell adhesion and loss of E-cadherin can suggest
are more aggressive phenotype by encouraging detachment from the primary tumor.
14

The first step in the transition from epithelial to mesenchymal transition (EMT) is considered the
loss of E-cadherin [22]. RagC is an important protein responsible for regulating the mTOR pathway
responsible for growth, proliferation, and survival in a cell. Preliminary data shows that in the
BT474 and BTLN2, EGFR a member of the HER family, is downregulated in the variant cell line.
Cytochrome C expression is downregulated in the variant BTLN2 as well, which has been found to
be downregulated in hypoxic tumors and known as a characteristic of tumor progression [23].
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Figure 4. Protein expression in MDA-MB-361 models. A) Shows HER-2 protein analysis in
MDA-MB-361 parental, and the tumorigenic variant 361p3. There seem to be no apparent change
in the HER-2 receptors. B) Shows analysis of mTOR pathway, B-actin is used as a control. In the
variant there is a downregulation of Phospho Akt and E-cadherin.
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Figure 5. Protein expression of BT474 parental and BTLN2 variant cell lines. A. Expression of different
proteins important for apoptosis. Changes are evident in Cytochrome C expression. B. Changes is protein
expression of HER-2 family receptors are seen in BTLN2 variant such as EGFR and phospho HER-3. Changes
in MAPK signaling proteins such as AKT and its phosphorylated form were also found.
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2.9 Discussion
Breast cancer is the most common type of cancer diagnosed in women worldwide. It continues to
be a major challenge although many breakthroughs in cancer research have been made. There is
still a need to overcome and understand why drug resistance emerges. Identifying protein and gene
expression differences in tumors before and after treatment is a way for us to unveil which of these
is responsible for driving drug resistance in breast cancers. Our protein analysis supports our
hypothesis that HER-2 positive breast cancer cells have different expression levels that allow these
to become resistant to chemotherapy and give them the ability to invade other organs. One common
example is the use of other survival compensatory programs such as Phosphatydil-inositol-3-kinase
(PI3K) that enable the abnormal cell growth to continue [26]. Here, we present that there are
changes in the PI3K pathway in the MDA-MB-361 cell line and its variant counterparts. Akt, an
important component of the PI3K pathway, is responsible different processes in the cell such as
regulating cell growth, motility, survival, and metabolism (Figure 5) [27]. Elevated levels of Akt is a
similarity of many cancers. At the same time, the expression of Rag C, a mediator of the MAPK
and mTOR pathways, is also downregulated. Once cells have acquired drug resistance, they can
often express or downregulate proteins that helps them continue to grow, survive, and proliferate.
Data suggests that there are changes in both parental and variant cell lines that may be responsible
for the aggressive phonotype acquired by the administration of chemotherapy. Such rationale can
be attributed to the change in expression of proteins such as Cytochrome C, RagC, Akt and EGFR
all important for cell growth proliferation, division, and survival (Figures 4 & 5).
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3: MODELS OF METASTASIS AND BIOMARKER STUDIES
Dissemination of tumor cells into other organs in the body is mediated by diverse cells surrounding
the tumors. Cancer cells will begin to acquire changes that will enable them to leave the primary
tumor and begin colonization in a distant organ. One of the most important processes regarding
metastasis is a process termed, Epithelial-Mesenchymal Transition (EMT) [26]. EMT is a process
where epithelial cells gain properties that are important for invasion, motility, and dissemination.
This program is first seen during embryogenesis and in wound healing, but cancer cells learn to
use this process to switch to a more motile and stem-like phenotype [28]. Transcription factors
associated with EMT are often Slug, SNAIL, Twist, zinc-finger-E-box-binding (ZEB-1), and pairrelated homeobox transcription factor 1 (Prrx-1) [28]–[30]. These transcription factors bind to Eboxes that repress the expression of E-cadherin, a protein that is commonly found in junctions of
epithelial cells, thus assisting this transition from epithelial to mesenchymal phenotypes [28]. Ecadherin provide epithelial cells polarity and integrity in different tissues; therefore, its expression
is crucial for the maintenance of cellular networks [31]. In cancer, E-cadherin expression is often
replaced by N-Cadherin, which is typically seen in the process of embryogenesis and wound
healing where cells must migrate to other tissues. Many cancers switch cadherin expression making
cells lose polarity, gain invasiveness, and encourage cell survival after loss of normal cell and
substrate interactions [31]. Many signaling pathways are involved in the progression of metastasis
and induction of EMT such as TNF-b, which is commonly known as the ‘master inhibitor of cell
cycle progression [32]. This cytokine is also necessary for the many different aspects of ECM
degradation, remodeling, and its production, which are necessary for tumor cells to successfully
detach from the primary tumor [32]. TNF-b has the ability to induce the expression Matrix
Metalloproteinases (MMPs), which degrade both ECM (extracellular matrix) and basement
19

membrane (BM), essential for invasion to other organs. TNF-b regulates plasminogens that control
degradation of proteins found in blood vessels that allow for intravasation into the bloodstream.
Once BCCs find their way into the bloodstream, they continue to interact with other cells that will
make their invasion feasible. BCCs will enter the bloodstream through a similar process; this is by
remodeling the endothelial cells that line blood vessels, then circulating the bloodstream before
exiting to begin colonization elsewhere. During the course of this process, cancer cells may cluster
together to avoid elimination by the immune system such as natural killer cells that supervise the
blood system for antigens. Cancer cells may become wedged in small capillaries and forcefully
begin to colonize. Cancer cells can be attracted by the different cytokine and chemokine factors to
homing tissues [33]. Different chemokines and cytokines will trigger circulating cancer cells and
endothelial cells to express surface proteins and receptors important for rolling and docking of
tumor cells into endothelial cells for intravasation [33]. E-selectin is a surface protein only found
in cytokine-activated endothelial cells and is responsible for interacting with leukocytes allowing
them entry into different tissues where inflammation and injury is taking place. For example, Pselectin glycoprotein ligand-1 expressed on BCCs will bind to E-selectin and permit rolling through
vascularity to gain entrance to invade other tissues. Once the cancer cells dock, these will with
loose Once in the bloodstream, these single cells or clusters of cells will encounter several cells of
the immune system and at the same time BCCs will express different receptors on their surface that
allow them to ‘home’ to different organs in the body.
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Figure 6. Formation of Metastasis. Diagram shows the many steps it takes for metastasis to occur.
A. Primary tumor continues to grow. B. In order for tumor to grow past 2mm in size, a bed of
capillaries must be established. C. Cancer cells begin to acquire invasive phenotypes that allow
them to detach from primary tumor. Surrounding stroma can be reorganized and degraded to allow
for intravasation to the blood vessels. D. Cells enter the blood vessels and use circulation to reach
other organs. If these cancer cells survive circulation they may get trapped in capillaries and adhere
to the blood vessel walls to begin extravasation. E. Cells will now exit the blood vessel and enter
new tissues and organs. F. Cells will establish in new organs, proliferate, and give rise to a new
secondary tumor or metastasis.
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3.1 Widespread metastasis
According to the ‘seed and soil’ hypothesis, circulating tumor cells do not randomly metastasize to
distant sites but rather preferentially grow in specific organs (i.e. the correct “soil”) [34]. For
example, patients suffering from breast cancer will most likely develop metastasis to the lung,
bone, liver, and brain[33], but not to other organs such as the skin [35]. Developing a model that
can reproduce this pattern in vivo helped unveil the underlying mechanisms, and allowed us to test
if a metastasis in a specific organ (e.g., the lung) can be more resistant to anticancer therapies than
metastasis to other sites. One way to establish widespread metastasis in vivo is to implant cancer
cells directly into heart (i.e., into the mouse left ventricle) and follow the progression of the
disease. Intracardiac injections have the advantage of allowing cancer cells to enter the blood
stream, without directing them to a specific organ for metastatic growth. This is in contrast to, for
example, to intravenous (tail vein) injection which invariably only produces lung metastases. In order to
further understand cancer spread and drug resistance in different organs, plasma samples from
gastrointestinal cancer patients enrolled in a clinical phase II trial were analyzed to determine
how their cytokine profile varied in the course of treatment. Our original aim was to obtain samples
of breast cancer patients (in line with our study on the above aims), but a perchance offer of samples
from a gastrointestinal clinical trial, in line with our IRB, made it possible for us to address this
question earlier than we had anticipated – albeit in a different cancer type.
Overall, the above approaches will allow us to address drug resistance in new preclinical models
and in clinical samples.
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3.2 Cytokines in Cancer
Cytokines are important signaling molecules that can stimulate and suppress the immune system.
They are involved in a wide range of effects such as recruitment of a various cell types of the
immune system and the downstream regulation of diverse cell signaling pathways. Macrophages,
B lymphocytes, T lymphocytes, endothelial cells, and fibroblasts are some examples of cells
known to release cytokines that can trigger an immune response [36]. They are important in a
number of processes, signaling during infection, wound, cancer, and reproduction[36]. We
evaluated the cytokine profile of cancer patients in a phase II clinical trial to see if we could
correlate cytokine levels with progression free survival (PFS). These types of studies may allow
for the future tailoring of specific therapies to those subgroups of patients most likely to show a
response.

3.3 Methods Preclinical metastatic model
Balb/c, wild type (WT), and B6-JA18KO (KO) mice were used to generate preliminary data. The
KO model lacks invariant natural killer T (iNKT) cells, allowing us to test whether such cells
can alter the metastatic process. iNKT cells are important in the regulation of immune response
via cytokine production [36]. First, we optimized the procedure in term of the number of cells
injected per mouse. We empirically determined that the optimal number is 2x105 in a 100ul volume
for B16F1 melanoma cells, and 7x103 EMT-6 breast cancer cells (in the same volume). In preliminary
experiments the B16-F1 melanoma was chosen to better visualize the metastatic sites as the
pigmented cells are black compared to the rest of the organs, Figure 5 shows an example of melanoma
to different organ sites.
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Figure 12. Modeling Metastasis though intracardiac implantation. Cancer cells such as EMT6 and B.16 melanoma were injected in the left ventricle of Balb/c and immunodeficient mice to
develop models of widespread disease.
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3.4 EMT-6 breast cancer model
HER-2 positive, murine breast cancer cell line, EMT-6, was then injected (7 x 103 following the
same protocol) into the heart of mice to test the efficacy of metronomic chemotherapy on late stage
breast cancer. Balb/c mice (40) were implanted intracardiacally with 7 x103 EMT-6 cells, and 4
treatment groups were then set up to receive control, anti-CTLA-4 immunotherapy, gemcitabine
chemotherapy or CTLA-4 plus chemotherapy. Metronomic Gemcitabine was administered
160mg/kg i.p. every three days and anti-CTLA-4 was administered 100ug i.p. on day one followed
by 35ug i.p. on day 6, either alone or in combination.

3.5 Relevance of cytokines in cancer patients of a phase II clinical trial.
Allegrini, et al conducted a phase II clinical trial for patients with refractory gastrointestinal tumors
[37]. 38 patients enrolled to receive UFT (100mg/day twice a day), Cyclophosphamide (50mg/day),
and Celecoxib (200mg/kg twice daily). Celecoxib was used as an angiogenesis inhibitor. UFT is a
prodrug that interferes with thymine synthesis, and Cyclophosphamide (CTX) is a DNA alkylating
agent. Metronomic CTX has been reported to inhibit angiogenesis by targeting endothelial cells and
upregulating thrombospondin-1 (TSP-1), a protein inhibits blood vessel formation[38]. Published
studies suggest that metronomic cyclophosphamide can activate the immune system [39]. The purpose
of the clinical trial was to evaluate the efficacy of a metronomic therapy in patients with late stage
gastrointestinal cancers no longer responding to standard chemotherapy.
As noted above, metronomic chemotherapy is thought to act, at least for CTX, by activating the
immune system. This led us to ask whether a complex therapy cocktail with CTX (plus the other
drugs; UFT and celecoxib) would also lead to immune system activation. To test this, a 14-bead
cytokine luminex panel was used, using the luminex technique, and applied to plasma samples
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from the Allegrini trial. To evaluate how cytokine levels could correlate with response to
chemotherapy in this phase II trial, analysis was carried out on plasma samples taken on Day 0
(i.e., before the start of treatment), Day 28, and Day 56 (Figure 14).

Figure 13. Plasma collection dates. Patients enrolled in clinical phase II trial had blood
drawn on days 0, 28, and 56 for cytokine level analysis.

Plasma samples of patients in clinical phase II trial were received from our colleague (Dr. Bocci)
at The University of Pisa and stored at -80°C. Samples of 38 patients were analyzed using Human
Cytokine/Chemokine Magnetic Bead Panel Cat No. HCYTOMAG- 60K (Millipore) with 14
different analytes. The samples and beads were incubated as per manufacturer’s protocol, then
plate was read using the Millipore Luminex Analyzer.

3.6 Gemcitabine
Gemcitabine (2’,2’-difluoro 2’-deoxycytidine, dFdC) is a widely used cytotoxic antimetabolite that
is FDA approved for the use in many solid tumors such as bladder cancer, ovarian cancer, head and
neck cancers, and breast cancer [40]. Gemcitabine is a cytidine analog that enters the cells through
SLC28 and SLC29 nucleoside transporters, the latter being the most efficient in uptake [41].
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Nucleoside kinases are responsible for converting cellular gemcitabine into its two active forms.
One of the active forms of gemcitabine, dFd-CTP, incorporates into growing DNA and DNA
synthesis is blocked immediately after another nucleoside is inserted. Masked chain termination
occurs as DNA proofreading enzymes fail to remove dFd-CTP from the DNA strand because of its
resistance to polymerase epsilon [42]. This leads to cell death in rapidly diving cells.

3.7 Anti-CTLA
Anti- CTLA-4 and Gemcitabine were used to combine the efficacy of immunotherapy and
metronomic chemotherapy against HER-2 positive breast cancer in a widespread metastasis and
brain metastasis models. Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is a receptor found in the
surface of T-cells that plays an important role in the inhibition of the immune system. There are
two signals that must occur for a T-cell to become activated; the presentation of an antigen by
antigen presenting cells (APCs) and binding of CD-28 on a T-cell and the B7 receptor of an APC.
On the other hand, CTLA-4 will bind to B7 and have a negative effect on T-cell activation. By
blocking this negative feedback of T-cell activation, anti-CTLA-4 antibody will allow for the
continual activation of T-cells, encouraging the immune system to attack cancer cells [43].

3.8 Results
The use of this intracardiac model produced preliminary data suggesting some preferred sites for
metastasis of B16-F1 melanoma cells. Thus, Figure 14 shows the distribution of metastases in
different organs. The data suggest that there are preferred sites for metastases such as liver, and
lung, and that the frequency can differ depending on the genetic background of the host. The
probability of liver metastasis is found to be higher in WT models (95% CI) (Figure 15). These
results show the feasibility of this approach, which were then used to set up therapeutic experiments
of breast cancer metastases in mice. Next, widespread metastases was set up in Balb/c mice through
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the implantation of EMT-6 breast cancer cells. Mice were then divided into groups, to be treated
with control or with chemotherapy regimens. Analysis at autopsy was then used to determine if
metastases at certain organs will promote drug resistance (as seen by an increase in metastases to
those organs in mice treated with chemotherapy). In the EMT-6 breast cancer model, we saw that
the combination of anti-CTLA-4 and Gemcitabine had the best percent survival when compared to
the treatments alone and controls (Figure 16). Gemcitabine alone had the second-best percent
survival at 24 days. Tumors cells extracted from each of the groups are now considered drug
resistant and can be used to further understand drug resistance.
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Figure 14. Metastasis of B16-F0 melanoma to different organ. B16-F1 melanoma cells were
intracardiacally implanted into mice to establish a protocol and a model of widespread metastasis.
Melanoma cells have deposited to the lungs, liver and ovaries of a mouse. The melanin produced by
these cells allows the visualization of the metastasis to the naked eye (circled in yellow).
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A

B

Figure 15. Total metastatic sites and correlation found in WT and B6-JA18KO models. A)
This graph reflects the number of times an organ had metastasis in a mouse totaling both KO and
WT models. B) WT mice are represented in blue and B6-JA18KO are represented in red. This is
data suggests that there are statistically significant differences between the two models.
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Figure 16. EMT-6 Breast cancer cells implanted in Balb/c mice. 40 mice were implanted breast
cancer cell line, EMT-6 intracardiacally and split into 4 different groups, Gemcitabine 120mg/kg,
anti-CTLA-4, combination of Gemcitabine and anti-CTLA-4, and control (PBS). Combination of
immunotherapy and chemotherapy had a better percent survival than other experimental groups.
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In the clinical samples analyzed, IL-6 and IL-8 plasma levels increased from baseline (at Day 0) to
Day 28 after treatment began (Figure 17). IL-6 levels in the tumor microenvironment have been
implicated in helping cancer cells by promoting survival, invasiveness, and metabolism [44]. On
Day 56, there was a further increase IL-6 and IL-8 levels, but not in (for example) IL-12a levels
(Figure 18). Patients who have better PFS, that is a longer period under treatment before disease
progression was observed, had distinct cytokine profiles compared to patients who did not show
much benefit from the metronomic therapy. Thus, at Day 56, patients with higher levels of IFNy
and lower levels of sCD40L eventually showed better PFS (Figure 18 A&B) than the rest of the
patients in this trial. Therefore, these cytokine levels, before metronomic chemotherapy started,
appeared to be predictive markers for good responders to this treatment.

Figure 17. Selective Cytokine Levels. Plasma levels measured in patients with late-stage
gastrointestinal cancer at Day 0, 28, and 56. There is an increase in both IL-6 and IL-8 as
chemotherapy continues in gastrointestinal cancers.
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Figure 18. Progression Free Survival and plasma cytokine l evels at Day 56. A) sCD40L
plasma levels in patients below 2173pg/ml (p= 0.0007) show better PFS than those above this value.
These values are consistent as well on days 0 and 28. B) IFNy levels above 29.83pg/ml (p=0.02)
show better PFS.
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3.9 Discussion
Metastatic disease remains the main challenge in the treatment of most cancers. Yet, the majority
of cancer therapeutic studies involve the study of primary tumors rather than frank metastatic
disease. As part of an effort to improve the in vivo models used to test new cancer therapies, we
have developed a model of intracardiac implantation of EMT-6 breast cancer cells injected to the
left ventricle of Balb/c mice. Our results show that the combination produced anti-tumor activity
in the metastatic setting. In addition, similar experiments using the B16 melanoma conformed the
usefulness of this intracardiac implantation technique to generate drug-resistant models of
widespread metastatic disease. Coupled with this experiment, our analysis of cytokine levels at
Day 56 confirmed that sCD40L and IFNy levels could be predictive markers for improved PFS.
Thus, longer PFS is found in patients with lower levels of sCD40L and higher levels of IFNy (Figure
18). This data suggests that there are possible cytokines such as sCD40L and IFNy that can serve as
biomarkers for patients who can benefit from this combination and regimen of chemotherapy.
Additional studies using clinical samples and preclinical samples from in vivo mouse experiments
will be necessary to confirm these results. Such studies will also be important to determine
whether the potential biomarkers we identified are unique to gastrointestinal cancers, or if they
can be applied to other tumor types such as breast cancers. These approaches improve our ability to
study late stages of cancer progression, and to evaluate new therapeutic concepts in more relevant
preclinical models.
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4: MODELING BRAIN METASTASIS
Brain metastasis has become more and more common in women with breast cancer. Patient
outcomes have improved leading to better survival thus increasing the incidence of brain
metastasis. 15 to 30% of patients who achieve long-term survival are known to have breast cancer
metastasize to the liver, bone, brain, and lungs. Breast cancer brain metastasis has poor prognosis,
limited life expectancy and quality of life. To reach better prognosis and quality of life, an
improvement in therapy must be achieved.
There is a higher chance of brain metastasis from breast or lung cancers than a brain primary tumor.
HER-2 positive breast cancer patients are most likely to develop brain metastasis than breast cancers
of other subtypes, such as luminal a and b subtypes. This can be attributed to the administration of
HER-2 targeted therapy such as trastuzumab, which cannot cross the blood brain barrier (BBB)
[45]. It is important to use HER-2 positive cell lines to represent the number of patients who
succumb to cancer once the disease spreads to the brain since overall survival for such patients is
about 16.5 months. Gene and protein expression can account for organotropism of breast cancer
metastasis. Many BCCs can express certain chemokine receptors, such as CXCR4, that make them
suitable for metastasizing to the brain where its ligand, CXCL12, is found in abundance [46], [47].
Sihto, et al., found an increased protein expression in primary breast cancer tumors and the site of
metastasis. Breast cancer cells (BCCs) migrate to the brain in the same manner they would to other
organs except that now they must penetrate the blood brain barrier (BBB). It is difficult for BCCs to
survive in the circulation after detachment from the primary tumor and invasion to the brain proves
to be a challenging task. The BBB is a composed of a layer of endothelial cells surrounded by a
basement membrane, pericytes, and astrocyte foot processes, which make it difficult to invade [48].
Astrocytes are capable of synthesizing a wide range of cytokines that cancer
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cells use to increase survival and invasiveness. These include IGF-1, TNFa, and PDGF-1 [47].
BCCs can rearrange the BBB by secretion of proteases [49]. Macrophages aid the invasion through
the BBB by releasing Vascular Endothelial Growth Factor (VEGF), thus inducing proliferation and
migration of endothelial cells (EC) and at the same time disrupting the tight junctions that hold ECs
together [48]. There are different ways in which a BCC migrates to the brain. Once the BCCs attach
to the endothelial cells, these are able to migrate through paracellular or transcellular migration. In
order for either process to occur, interactions between vascular endothelial cells and BCCs must
take place. For instance, vascular endothelial cell express Notch ligands that will interact with the
Notch receptors expressed on the BCC, then intracellular junctions are disrupted and reorganized
during paracellular migration [50].

4.1 Current Models of Metastasis
Current experimental models of metastasis include tail vein injection, carotid vein, intra-portal, and
intracardiac. Tail-vein injection often results in lung metastasis, as this is the first set of capillaries
that cells encounter when they enter the bloodstream [51]. Intracecal injection of cells tend to
metastasize to the liver through the portal vein. The use of intracardiac injection permits the
widespread metastasis throughout the body without forcing a tumor to a specific organ. Intracardiac
implantation of cancer cells give metastasis to liver, lung, bone, mesentery, ovary, kidney, etc.

4.2 Stereotactic Surgery Methods
Mice were first prepared for injection following IACUC guidelines. Stereotactic equipment was
inspected to make sure it is leveled to ensure proper site of injection. Mice were anesthetized with
isoflurane 5% in ~1L/min oxygen from a precision vaporizer then placed in the stereotactic
apparatus with its mouth and teeth properly fixed on mouthpiece for proper flow of anesthetic and
oxygen (1-2% isoflurane for maintenance). Ophthalmic ointment (Lacri-lube) was put on the
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mouse’s eyes once the animal was placed on the stereotactic apparatus. Incision site was shaved
and swabbed three times alternating 70% alcohol and chlorohexidine with one last application of
chlorohexidine scrub. Buprenorphine (0.05mg/kg) was administered s.c. before the incision of the
skull was made. Bregma and Lambda are clearly seen by the addition of 30% hydrogen peroxide
using a swab directly on the skull. In order to make sure that the incision is made correctly, Bregma
and Labmba were used as to establish a leveled cranium. From Bregma, the following coordinates
were used: 2mm posterior to Bregma, 1mm to the left of Bregma, and 3mm deep. A Hamilton
syringe needle was used to mark the site of injection, then a hand-held drill was used to drill through
the cranium to expose the brain. 2.5x107 BTGF1 ells were injected at a rate of 1ul/min over the span
of three minutes. After cells had been injected, the needle was left in the brain for an additional minute
to prevent any cells from spilling into other parts of the brain. Once needle is taken out of the brain,
a piece of brain wax is smeared on top of the skull to conceal the incision made. Skin is sutured
promptly, and topical antibiotic is applied over the incision to avoid infection of SCID mice. Postsurgical monitoring took place daily and an additional dose of buprenorphine (0.05mg/kg, i.p.) was
administered 14 hours after surgery.
Tumor progression was monitored weekly after i.p. injection of Luciferase. Mice were then imaged
using In Vivo Imaging System (IVIS) shortly after injection of luciferase. Luminescence was
plotted using Prizm version 6.0.

4.3 Lapatinib
Lapatinib is an FDA approved tyrosine kinase inhibitor of HER-1 (EGFR) and HER-2 for use in
combination with capecitabine, trastuzumab, or hormone therapy for advanced HER-2 positive
breast cancer and gastrointestinal cancer patients. Lapatinib binds to the tyrosine kinase domain of
the HER family receptors leading to the downstream signaling cascade, blocking tumor cell growth
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[7]. Lapatinib has been widely used in the clinic to treat HER-2 positive breast cancer, but the use
of other HER-2 targeted therapies are preferred due to efficacy. The use of Lapatinib is still
preferred for cancers with truncated HER-2 and brain metastasis since it has the ability to easily
cross the BBB [7]. To test the efficacy of Lapatinib in a metastatic breast cancer to the brain, it was
administered orally via gavage (50mg/kg) to HER-2 positive cell line BTGF1.

4.4 Results
In the preliminary studies using Lapatinib as the drug of choice in brain metastasis models, our
experimental group was not helpful in inhibiting tumor growth, shown as photons p/s in Figure 19.
Mice in the control group had lower levels of luminescence throughout the span of the experiment.
Due to these results, the drug of choice was changed to Gemcitabine to develop a second metastatic
model of acquired drug resistance. Mice administered gemcitabine had larger tumors on average at
the start of the experiment and had smaller tumors after the second week of treatment (Fig. 20).
Luminescence was visualized weekly to determine tumor progression in these metastatic models
(Fig. 21). Mice in the Gemcitabine group responded to treatment by week 2 and by week 5 these
tumors began to show drug resistance.
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Figure 19. Lapatinib tested on BTGF1 brain metastasis model. Shows brain metastasis
progression in both Control (PBS) and Lapatinib (50mg/kg) treated mice over the period of 7 weeks.
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Figure 20. Visualization of luciferase positive, BTGF1 brain metastasis model. Top panel
shows the efficacy of Gemcitabine (120mg/kg) given every 3 days i.p. On week 2, tumor
luminescence increases, but after the 6th dose of metronomic Gemcitabine, the tumor begins to
shrink at week 3. Bottom panel shows the increase in luminescence from week 1 to week 3, cancer
continues to progress in control group.
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Figure 21. Tumor Growth curve of BTGF1 cells in SCID mice. SCID mice were injected 2.5x105
BTGF1 cells intracranially. SCID mice (n=9) treated with Lapatinib (50mg/kg) via daily gavage.
Control group (n=9) was administered PBS via daily gavage.
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4.5 Discussion
Thanks to the many scientific advances and breakthroughs, the 10-year survival rate for breast
cancer patients is now 85%. Unfortunately, this is not the case for metastatic breast cancer. Due to
this increased survival rates for breast cancer patients, metastasis incidences to the brain are also
on the rise. In this sense, breast cancer patients are living longer and now have higher chances of
developing metastasis in their lifespan. It is important to note that brain metastasis from primary
breast tumors are more common than a primary brain tumor. 24% of patients suffering from breast
metastasis to the brain have a 2-year overall survival. Thus, it is imperative to model brain
metastasis in vivo to study the mechanisms of disease taking place within these tumors to find
potential therapeutic targets. The preferred site of invasion for patients treated with HER-2 targeted
therapy is the brain [52]. The HER-2 positive brain metastasis models developed in this project
have also been used to metronomically administer HER-2 targeted chemotherapy to improve
treatment options. As the results suggested, the models have successfully been developed and
therapy was tested against them. The next step in this project is to continue testing other therapies
and combinations. One such treatment that can be used is Osimertinib, which is a tyrosine kinase
inhibitor approved for small lung carcinomas that targets EGFR. Osimertinib in combination with
other chemotherapies can target those mechanisms of drug resistance that HER-2 positive breast
cancers usually present. Literature suggests that EGFR is often upregulated as a means for cancer
cells to become drug resistant in HER-2 positive cancers [53].
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5: CONCLUDING REMARKS
About 90% of cancer patients will die because of metastatic disease [28]. It is therefore important
to develop models that recapitulate the steps by which cancers metastasize, and those include the
detachment of cancer cells from the primary tumor, the survival the circulation, and the eventual
arrest and growth at a distant organ. It is also important to study such preclinical models together
with the administration of therapies that reflect current treatment options in the clinic. The use of
advanced cancer models for experimental therapeutics should improve our understanding of the
process of metastasis, and increase our knowledge of how cancer cells can stop responding to
certain therapies. Such studies should eventually also allow us to develop new therapies. This
project addressed the unmet need for HER-2 positive breast cancer models that can accurately
represent late-stage disease in patients. There have been many improvements to patient care and
treatment, but the mortality rates for breast cancer patients with metastasis continues to rise. The
current models of disease are often not reproducible, too artificial, unreliable, or respond too well
to the therapy administered. In order to overcome some of the current issues with modeling disease
for such patients, several models of HER-2 positive breast cancer models were characterized,
developed, and tested against metronomic chemotherapies. BT474 and MDA-MB-361 are two
HER-2 positive breast cancer cell lines readily available and were used to select for more
aggressive and drug resistant populations. After several cycles of implantation, these cells lines
grew faster in vivo and gave us the opportunity for using them in a widespread model and brain
metastasis model. These in vivo models were then tested against current FDA-approved therapies
in a metronomic or low-dose fashion. These newly developed breast cancer models are important
to study the differences in protein expression between primary breast cancer populations, and
tumor variants selected for aggressive growth in vivo and/or resistance to anti43

cancer therapies. This work identified new markers of either cancer progression or of acquired drug
resistance. Furthermore, using an in vivo model of widespread metastasis, by the intracardiac
implantation of tumor cells in mice, relative drug resistance of a tumor cell population is dependent
on the organ in which it is growing. These studies were conducted alongside analysis of plasma
samples from cancer patients in a clinical trial. Specifically, I have looked at cytokines profiles of
patients responding to, and not responding to, a metronomic chemotherapy treatment strategy.
Certain cytokine profiles indicate a relative level of drug resistance in the tumor of a given patient,
as indicated by reduced progression free survival compared to other patients. Altogether, these
efforts have contributed to our understanding of how cancers respond to currently available
therapies, and how drug resistance in some cases emerges.
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GLOSSARY
APCs Antigen Presenting Cells
BBB Blood Brain Barrier
BM Basement Membrane
CEACAMs Carcinoembryonic antigen-related cell adhesion molecules
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4
CTX Cyclophosphamide
EC Endothelial Cell
EGFR Epidermal Growth Factor Receptor
EMT Epithelial to Mesenchymal Transition
HER-2 Human Epidermal Receptor 2
IGF-1 Insulin-like Growth Factor-1
IVIS In Vivo Imaging System
KO Knockout
MMPs Matrix Metalloproteinases
PBS Phosphate Buffered Saline
PDGF-1 Platelet Derived Growth Factor-1
PFS Progression Free Survival
PI3K Phosphoinositide 3-kinases
Prrx-1 Paired related homeobox 1
PTEN Ten-sin Homolog
TAM Tumor Associated Macrophages
TNFa Tumor Necrosis Factor Alpha
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TSP-1 Thrombospondin 1
WT Wild-type
ZEB-1 zinc finger Eboxbinding homeobox 1
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